Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.

Middleton, G; Silcocks, P; Cox, T; Valle, Juan W; Wadsley, J; Propper, D; Coxon, F; Ross, P; Madhusudan, S; Roques, T; Cunningham, D; Falk, S; Wadd, N; Harrison, M; Corrie, Pippa; Iveson, Tim; Robinson, A; McAdam, K; Eatock, M; Evans, J; Archer, C; Hickish, T; Garcia-Alonso, A; Nicolson, M; Steward, W; Anthoney, A; Greenhalf, W; Shaw, V; Costello, E; Naisbitt, D; Rawcliffe, C; Nanson, G; Neoptolemos, J

Affiliation

University of Birmingham, Edgbaston, Birmingham, UK.

Issue Date

2014-07

Metadata

Show full item record

Abstract

We aimed to assess the efficacy and safety of sequential or simultaneous telomerase vaccination (GV1001) in combination with chemotherapy in patients with locally advanced or metastatic pancreatic cancer.

Citation

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. 2014, 15 (8):829-40 Lancet Oncol

Journal

The Lancet Oncology

URI

http://hdl.handle.net/10541/322604

DOI

10.1016/S1470-2045(14)70236-0

PubMed ID

24954781

Type

Article

Language

ISSN

1474-5488

Collections

All Christie Publications